Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland need volunteers with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to participate in an investigational study testing the safety and effectiveness of ibrutinib, short-course fludarabine, and pembrolizumab in treating this condition. Eligible volunteers must either have received treatment for CLL and relapsed or have high-risk genetic changes, regardless of prior treatment. Volunteers will participate in the study for at least one year or longer and treatment may continue indefinitely. All study-related tests and procedures are provided at no cost to participants. Travel may be reimbursed.

**Study involves:**
- Multiple visits to the NIH Clinical Center for at least one year
- Administration of the study medications by mouth or by infusion
- A physical exam and medical history
- Collection of blood and urine samples

**You may be eligible if you:**
- Are at least 18 years old
- Have been diagnosed with active CLL or Hodgkin lymphoma
- Have received treatment for CLL and do not have low-risk genetic changes OR have high-risk genetic changes such as deletion 17p, TP53 mutation, NOTCH1 mutation or complex cytogenics

*The NIH Clinical Center, America’s research hospital, is in Bethesda, Maryland, on the Metro red line (Medical Center stop).*

NIH Clinical Center’s Office of Patient Recruitment
1-800-411-1222 (TTY: 1-866-411-1010)
se habla español
or go online, clinicaltrials.gov
Refer to study #17-H-0118